Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
There are two different treatment modes for NSCLC patients who failed to epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after initially responding to EGFR-TKI.
One is EGFR-TKI combined with chemotherapy and the other is chemotherapy followed by
EGFR-TKI. It is unclear which one is more suitable to this group of lung cancer patients. So
this phase â…¡clinical trial is designed to compare the efficiency and safety of these two
different treatment modes.